Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockMolecular Profile
Molecular Profile
Type
Synthetic peptide (acylated, 29 residues)
Molecular formula
C192H289N47O61
Molecular weight
~4,232 g/mol
CAS number
2805997-46-8
Amino acids
29
Fatty acid chain
C18 diacid
Modification
Position 2 substituted with Ac4c (1-aminocyclobutane-1-carboxylic acid); Lys-24 side chain acylated with an 18-carbon fatty diacid for albumin binding and extended half-life.
Mechanism & Target Class
Mechanism & Target Class
Survo is a 29-residue synthetic peptide that engages class B G protein–coupled receptors. Its backbone carries substitutions including a non-natural amino acid at position 2 (Ac4c, 1-aminocyclobutane-1-carboxylic acid). An 18-carbon dicarboxylic acid covalently attached to the Lys-24 side chain confers reversible albumin binding, extending plasma half-life. These structural features — non-coded residues and fatty-acid acylation — are shared with other long-acting class B GPCR ligands studied in this research area.
Storage & Handling
Storage & Handling
Lyophilized
20°C with desiccant
avoid repeated freeze–thaw; lyophilized form is stable for extended periods when properly stored and sealed.
Aliquoting minimizes freeze-thaw degradation; near-neutral pH buffers are suitable for solution stability; sterile conditions minimize oxidative and microbial exposure.
References
References
Reviews
- 1
Winther JB, Holst JJ. (2024). Diabetes Obes Metab
- 2
Novikoff A, Müller TD. (2023). Peptides
Reviews
- 3
Kajani S, Laker RC, Ratkova E, et al. (2024). Physiol Rev
- 4
Alfaris N, Waldrop S, Johnson V, et al. (2024). EClinicalMedicine
- 5
Wen J, How-Volkman C, Truong A, et al. (2024). Cureus
- 6
Yao Z, Wang C, Zhu Q, et al. (2023). Peptides
- 7
Li M, Hu J, Chin YH, et al. (2025). Front Endocrinol
- 8
Mantovani A, Morandin R, Fiorio V, et al. (2025). Liver Int
- 9
Stachteas P, Nasoufidou A, Karakasis P, et al. (2025). Rev Cardiovasc Med
- 10
Zafer M, Tavaglione F, Romero-Gómez M, et al. (2025). Aliment Pharmacol Ther
Primary research
- 11
Le Roux CW, Steen O, Lucas KJ, et al. (2024). Lancet Diabetes Endocrinol
- 12
Sanyal AJ, Bedossa P, Fraessdorf M, et al. (2024). N Engl J Med
- 13
Sanyal AJ, Mazo DF, Younes R, et al. (2024). J Hepatol
- 14
Thomas L, Martel E, Rist W, et al. (2024). Diabetes Obes Metab
- 15
Romero-Gómez M, Lawitz E, Shankar RR, et al. (2023). J Hepatol
- 16
Zimmermann T, Thomas L, Baader-Pagler T, et al. (2022). Mol Metab
- 17
Li Y, Zhou Q, Dai A, et al. (2023). Proc Natl Acad Sci USA
- 18
Corbin KD, Carnero EA, Allerton TD, et al. (2023). Obesity (Silver Spring)
- 19
Shankar SS, Daniels SJ, Robertson D, et al. (2024). Clin Gastroenterol Hepatol
- 20
Zimmermann T, Bleymehl K, Haebel P, et al. (2026). Mol Metab
Primary Database
Primary Database
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
